Table 1.
Inclusion and exclusion criteria.
Fig 1.
Schedule of enrolment, interventions, and assessments (SPIRIT figure).
Participation duration: 64 days, or 9 weeks and 1 day. Duration of participant exposure to interventions: 14 days (placebo), 14 days (Transvamix®). DN-4: douleur neuropathique 4, CSI: central sensitization inventory, PCS: pain catastrophizing scale, SF-MPQ2: short form McGill pain questionnaire 2, PSEQ: pain self-efficacy questionnaire, VAS Pa/Pr: visual analogue scale pain/pruritus, fMRI: functional magnetic resonance imaging.
Table 2.
Titration scheme employed by study participants.